Litcius/Paper detail

Non-Overt Coagulopathy in Non-ICU Patients with Mild to Moderate COVID-19 Pneumonia

Daniela Mazzaccaro, Francesca Giacomazzi, Matteo Giannetta, Alberto Varriale, Rosa Scaramuzzo, Alfredo Modafferi, Giovanni Malacrida, Paolo Righini, Massimiliano M. Marrocco‐Trischitta, Giovanni Nano

2020Journal of Clinical Medicine38 citationsDOIOpen Access PDF

Abstract

Introduction: Aim of the study is to assess the occurrence of early stage coagulopathy and disseminated intravascular coagulation (DIC) in patients with mild to moderate respiratory distress secondary to SARS-CoV-2 infection. Materials and methods: Data of patients hospitalized from 18 March 2020 to 20 April 2020 were retrospectively reviewed. Two scores for the screening of coagulopathy (SIC and non-overt DIC scores) were calculated. The occurrence of thrombotic complication, death, and worsening respiratory function requiring non-invasive ventilation (NIV) or admission to ICU were recorded, and these outcomes were correlated with the results of each score. Chi-square test, receiver-operating characteristic curve, and logistic regression analysis were used as appropriate. p Values < 0.05 were considered statistically significant. Results: Data of 32 patients were analyzed. Overt-DIC was diagnosed in two patients (6.2%), while 26 (81.2%) met the criteria for non-overt DIC. Non-overt DIC score values ≥4 significantly correlated with the need of NIV/ICU (p = 0.02) and with the occurrence of thrombotic complications (p = 0.04). A score ≥4 was the optimal cut-off value, performing better than SIC score (p = 0.0018). Values ≥4 in patients with thrombotic complications were predictive of death (p = 0.03). Conclusions: Overt DIC occurred in 6.2% of non-ICU patients hospitalized for a mild to moderate COVID-19 respiratory distress, while 81.2% fulfilled the criteria for non-overt DIC. The non-overt DIC score performed better than the SIC score in predicting the need of NIV/ICU and the occurrence of thrombotic complications, as well as in predicting mortality in patients with thrombotic complications, with a score ≥4 being detected as the optimal cut-off.

Topics & Concepts

MedicineCoagulopathyCoronavirus disease 2019 (COVID-19)Pneumonia2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Intensive care medicineVirologyInternal medicineInfectious disease (medical specialty)OutbreakDiseaseCOVID-19 Clinical Research StudiesSepsis Diagnosis and TreatmentLong-Term Effects of COVID-19
Non-Overt Coagulopathy in Non-ICU Patients with Mild to Moderate COVID-19 Pneumonia | Litcius